BRD4-IN-41 is a BRD4 inhibitor with an IC 50 of 34 nM. BRD4-IN-41 also inhibits JAK2 , FLT3 , RET , ROS1 , NTRK3 , PDGFRb , and FGFR1 kinases with IC 50 values ranging from 0.9 nM to 43 nM. BRD4-IN-41 inhibits acetyl-lysine binding site of BRD4, downregulates c-MYC , reduces phosphorylated STAT3 levels, induces G1 cell cycle arrest and apoptosis , thereby inhibiting cancer cells growth. BRD4-IN-41 can be used for the research of cancer , such as multiple myeloma and acute myeloid leukemia.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Multiple Myeloma | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > RET | Products > Signaling Pathways > ROS Kinase | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > FGFR | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > STAT | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PARP | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > JAK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye